BCAL Diagnostics Limited (BDX.AX)
- Previous Close
0.0950 - Open
0.0950 - Bid 0.0920 x --
- Ask 0.0990 x --
- Day's Range
0.0950 - 0.0950 - 52 Week Range
0.0700 - 0.2100 - Volume
110,556 - Avg. Volume
220,783 - Market Cap (intraday)
23.968M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
www.bcaldiagnostics.comRecent News: BDX.AX
Performance Overview: BDX.AX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BDX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BDX.AX
Valuation Measures
Market Cap
23.97M
Enterprise Value
20.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-134.82%
Return on Assets (ttm)
-34.87%
Return on Equity (ttm)
-73.51%
Revenue (ttm)
3.71M
Net Income Avi to Common (ttm)
-5M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.02M
Total Debt/Equity (mrq)
24.77%
Levered Free Cash Flow (ttm)
-2.51M
Company Insights: BDX.AX
BDX.AX does not have Company Insights